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ORIGINAL ARTICLE
A randomized phase II trial of interleukin-2 and interferon-a plus bevacizumab
versus interleukin-2 and interferon-a in metastatic renal-cell carcinoma (mRCC):
results from the Danish Renal Cancer Group (DaRenCa) study-1
Frede Donskova, Niels Viggo Jensenb, Torben Smidt-Hansena, Line Brønduma and Poul Geertsenc
aDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark; bDepartment of Oncology, Odense University Hospital, Odense,
Denmark; cDepartment of Oncology, Herlev Hospital, University of Copenhagen, Denmark
ABSTRACT
Background: Interleukin-2 (IL2)-based immunotherapy is curative for a small subset of patients with
metastatic renal-cell carcinoma (mRCC). Preclinical data suggests that bevacizumab (BEV), a humanized
anti-VEGF monoclonal antibody, has potential immunomodulatory effects by permitting efficient nat-
ural killer (NK) cell-mediated killing and by reverting immune suppression.
Patient and methods: We performed a randomized phase II study comparing IL2/IFN (interferon)/BEV
with IL2/IFN in favourable/intermediate-risk mRCC patients. One hundred and eighteen patients
received IFN 3 MIU subcutaneously (sc) daily and IL2 2.4 MIU/m2 sc twice daily, 5 days per week for
two consecutive weeks every 28-day-cycle, for 9 months; or supplemented with BEV 10mg/kg, every
2 weeks intravenously (iv) until progression, unacceptable toxicity, or 1 year following no evidence of
disease (NED). Primary end point was progression-free survival (PFS).
Results: Baseline characteristics were well-balanced between the two arms; metastasis-free interval
<1 year (75 versus 76%); prior nephrectomy (85 versus 86%); MSKCC favourable/intermediate-risk
group (51/49 versus 52%/48%); three or more disease sites (41 versus 44%), respectively. The median
PFS was 8.0mo (95% CI, 4.2–11.9) with IL2/IFN/BEV and 8.1mo (95% CI, 5.1–11.0) with IL2/IFN, p¼ .73.
There was no difference in secondary endpoints, IL2/IFN/BEV versus IL2/IFN; median time-to-treatment
failure (7.4 versus 5.6mo, p¼ .54), response rate (44.1 versus 28.8%, p¼ .13), surgery of residual disease
(17.0 versus 17.0%, p¼ 1.0), patients achieving NED (3.4 versus 8.5%, p¼ .44), and median overall sur-
vival (30.3 versus 34.1mo, p¼ .39), respectively. TKI post progression was well-balanced (85 versus
78%). No new/unexpected toxicity was observed. Most common Grade 3/4 adverse events for IL2/IFN/
BEV and IL2/IFN were fatigue (64 versus 61%), flu-like symptoms (37 versus 41%) and thrombosis (6.8
versus 18.6%, p¼ .01), respectively.
Conclusions: The addition of BEV to IL-2/IFN did not add efficacy in mRCC. (ClinicalTrials.gov,
NCT01274273.).
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Introduction
For decades, immunotherapy has been established therapy
for the treatment of patients with mRCC. The cytokine IL2
was discovered in 1976 [1], cloned in 1983 [2] and approved
in 1992 by the US Food and Drug Administration for the
treatment of patients with mRCC. This drug is curative for a
small subset of patients with mRCC [3,4]. Recently, the check-
point inhibitor nivolumab demonstrated improved overall
survival (OS) compared with contemporary standard therapy
in second-line mRCC and received regulatory approval in
2015 [5], but long-term follow-up data from responding
patients are still pending.
The understanding of clear-cell RCC as a source of excess
vascular endothelial growth factor (VEGF) production, due to
inactivation of the von-Hipple Lindau tumor suppressor
gene, has led to the development of anti-angiogenic therapy
[6]. Sustained inhibition of VEGF with BEV, a humanized anti-
VEGF monoclonal antibody, results in the regression of exist-
ing tumour microvasculature and inhibition in the formation
of new vasculature [7,8]. It may also revert tumor-associated
immune suppression [9], improve concomitant drug delivery
into the tumour [10,11] and permit efficient natural killer
(NK) cell-mediated killing [12].
BEV was the first anti-VEGF therapy to demonstrate clinical
benefit in mRCC, and other tumours [13]. In mRCC patients,
the addition of BEV to IFN compared with IFN alone
produced statistically significant improvements in progres-
sion-free survival (PFS) and response rates [14,15]. BEV in
combination with low-dose [16] or high-dose IL2 [17] was
feasible in non-randomized trials, with response rate and PFS
at least as high as reported previously for the single agents.
BEV, IFN and IL2 all have stimulatory effects on the
immune response and these three agents may have comple-
mentary and synergistic effects when combined [18]. We
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report the results from the Danish Renal Cancer Group
(DaRenCa) study-1, a randomised phase II study to evaluate
the efficacy and safety of BEV/IL2/IFN vs. IL2/IFN alone in
patients with mRCC.
Patients and methods
Patients
DaRenCa-1 was an investigator-initiated, randomised, open-
label phase 2 study. The study was run within the multidiscip-
linary national DaRenCa group with patients enrolled at two
centres in Denmark. Eligibility criteria were patients
18 years, with locally advanced or metastatic RCC, a clear-
cell histology component, no prior treatment, measurable dis-
ease per RECIST v.1.1 [19], Memorial Sloan Kettering Cancer
Center (MSKCC) favourable or intermediate risk [20], Karnofsky
Performance Status 70%, and adequate organ function
(based on standard laboratory tests including hematology,
serum chemistry, coagulation and urinanalysis). Exclusion cri-
teria were brain metastases, spinal cord compression, uncon-
trolled hypertension, clinically significant cardiovascular or
wound healing comorbidities, or corticosteroid requirement
10mg/day. The study was approved by the Danish
Medicines Agency, the Regional Research Ethics Committee,
and the Danish Data Protection Agency; and adhered to the
Good Clinical Practice guidelines and the Declaration of
Helsinki. All patients provided written informed consent. The
study was registered at ClinicalTrials.gov, NCT01274273.
Patients were randomised 1:1 to receive IL2 and IFN-a or
IL2 and IFN plus BEV. Randomisation was stratified by MSKCC
risk group [20] utilizing a stratified permuted blocks design.
Study personnel did not have access to the master list. This
was an open-label study to allow appropriate management
of adverse events.
Treatments
All cytokines were administered subcutaneously (s.c.) over
4-week cycles for up to a maximum of 9 cycles (i.e.,
9 months): IFN was given as a fixed dose, 3.0 MIU s.c. once
daily for 5 days per week commencing with a priming-week
of daily IFN. IL2 was given 2.4 MIU/m2 s.c. two times daily,
5 days per week, Weeks 1 and 2 every 4-week cycle. BEV at
doses of 10mg per kg of body weight was given every
2 weeks intravenously (i.v.) until disease progression,
unacceptable toxicity, withdrawal of consent or a maximum
of 1 year following obtaining no evidence of disease (NED).
Treatment interruptions, dose reductions or discontinua-
tions were allowed to manage adverse events. In case of
Grade 3 toxicity, with fatigue and fever as exceptions, ther-
apy was delayed until toxicity was Grade 2 or less. For hep-
atic or renal Grade 3 toxicity, IL2 and IFN were dose reduced
50%. Intravenous (IV) fluid was allowed to prevent hypoten-
sion or renal toxicity. No dose reduction for BEV was permit-
ted. In case of Grade 4 toxicity therapy was permanently
discontinued. Crossover between treatment groups was not
permitted. Physical examination, vital signs, laboratory assess-
ments and urinalysis were conducted every 2 weeks for the
first 4 weeks and then every 4 weeks thereafter. Adverse
events were graded according to CTCAE v.30.CT were con-
ducted at screening and every 12 weeks for the first 2 years
and then every 6-months thereafter. Tumour response and
progression were assessed by local radiologists according to
Response Evaluation Criteria in Solid Tumours (RECIST) v.11
[19]. Patients were not allowed to continue treatment if clin-
ical benefit and/or biochemical improvements were seen in
spite of radiological progression according to RECIST 1.1.
Pseudoprogression was newer a challenge.
Endpoints
The primary endpoint was PFS, defined as the time from ran-
domisation to date of progression per RECIST v.11 or death.
Secondary endpoints were objective response rate (ORR), OS,
time-to-treatment failure (TTF), tolerability, frequency of sur-
gical resection of residual disease and frequency of NED. TTF
was defined as time from randomisation to date of disease
progression, death, withdrawal of treatment due to adverse
events or laboratory abnormality, or withdrawn informed
consent. Overall survival was defined as the time from ran-
domisation to date of death from any cause, and ORR was
defined as the proportion of patients experiencing best
objective response as complete or partial response per
RECIST 11.
Statistical analysis
The study was designed to provide adequate power for
detecting a statistically significant difference in the primary
endpoint of PFS. Assuming a median progression-free sur-
vival of 5 months in the IL2/IFN arm and 9 months in the
IL2/IFN/BEV arm, corresponding to an 80% improvement in
PFS, then 85 events were required to achieve overall 80%
power of the log rank test at a two-sided overall 5% a-level.
In order to see the required number of events within the
planned study duration a total of 118 patients were required.
Median duration of PFS, TTF and OS, corresponding 95% con-
fidence intervals, were estimated by the Kaplan–Meier
method. All analyses were conducted using SPSSVR software
(IBM Corporation, Armonk, NY, USA) v.20.
Results
Patient characteristics
From 26 October 2009 through 21 November 2014, at two
Danish centres 118 patients were randomised to receive IL2/
IFN/BEV (n¼ 59) or IL2/IFN (n¼ 59) and followed until study
closure 31 May 2017. Preliminary data were presented at the
American Society of Clinical Oncology (ASCO) 2016 Annual
Meeting [21]. Updated and final data as of 31 May 2017 are
now presented. At the time of study closure, 113 patients
had progressed, 78 patients had died, and 7 patients had
NED. Median follow-up of patients alive was 64 months
(range 28.5–88.1 months). Baseline characteristics were well-
balanced between the two arms (Table 1); metastasis-free
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interval <1 year (75 versus 76%); prior nephrectomy (85 ver-
sus 86%); MSKCC favourable/intermediate-risk group (51/49
versus 52%/48%); three or more disease sites (41 versus
44%), and metastases to lungs (80 versus 83%) lymph nodes
(63 versus 63%), and liver (14 versus 15%), respectively. The
extent of bone metastases were higher in the IL2/IFN/BEV
arm (27%) versus than in the IL2/IFN arm (15%), the differ-
ence was not statistically significant (p¼ .18).
Treatment
Median duration of exposure was similar in the two groups:
seven cycles (range, 0–9) in IL2/IFN/BEV and six cycles (range,
0–9) in the IL2/IFN arm. The most frequent reasons for early
treatment discontinuation in the IL2/IFN/BEV versus IL2/IFN
groups were disease progression (63 versus 49%) and
adverse events (19 versus 15%), respectively.
Efficacy
There was no difference in the primary endpoint between
IL2/IFN/BEV and IL2/IFN; the median PFS was 8.0mo (95% CI,
4.2–11.9mo) with IL2/IFN/BEV and 8.1mo (95% CI,
5.1–11.0mo) with IL2/IFN, p¼ .73 (Figure 1(A)).
There was no difference in secondary endpoints between
IL2/IFN/BEV and IL2/IFN; best ORR (44.1 versus 28.8%, p¼ .13)
(Table 2 and Figure 2); surgery of residual disease (17.0 ver-
sus 17.0%, p¼ 1.0); and patients achieving NED (3.4 versus
8.5%, p¼ .44). Median TTF was 7.4mo (95% CI 4.4–10.3mo)
with IL2/IFN/BEV versus 5.6mo (95% CI, 2.6–8.5mo) with IL2/
IFN, p¼ .54 (Figure 1(B)) and median OS was 30.3mo (95%
CI, 20.6–40.0mo) with IL2/IFN/BEV versus 34.1mo (95% CI,
19.9–48.2mo) with IL2/IFN, p¼ .39 (Figure 1(C)).
Similar proportions of patients in the IL2/IFN/BEV and IL2/
IFN groups had subsequent systemic anticancer therapy fol-
lowing study treatment discontinuation with no statistically
significant difference between subgroups (85 versus 78%)
(Table 1).
Exploratory analysis showed disparate outcomes for IL2/
IFN/BEV versus IL2/IFN in MSKCC favourable and intermedi-
ate-risk groups. Patients with MSKCC favourable risk treated
with IL2/IFN/BEV versus IL2/IFN had PFS 5.9 versus 8.5mo,
p¼ .18, TTF 5.5 versus 8.1mo, p¼ .34 and OS 31.3 versus
64.6 mo, p¼ .018, respectively. Patients with MSKCC inter-
mediate risk treated with IL2/IFN/BEV versus IL2/IFN had PFS
9.4 versus 2.9mo, p¼ .17, TTF 8.5 versus 2.9mo, p¼ .17 and
OS 27.4 versus 18.9mo, p¼ .32, respectively.
Figure 1. Kaplan–Meier plot of (A) progression-free survival, (B) TTF and (C) OS. All 118 randomised patients were included in the analysis. The number of patients
censored is summarized by interval. Black line: IL2/IFN/BEV, dotted line IL2/IFN.
Table 1. Demographics and baseline characteristics.
IL-2/IFN/BEV IL-2/IFN
N¼ 59 N¼ 59
Age, years (range) 58 (28–70) 55 (37–69)
Sex, n (%)
Male 46 (78) 47 (80)
Karnofsky PS, n (%)
100 31 (53) 37 (63)
90 19 (32) 16 (27)
80 6 (10) 4 (7)
70 3 (5) 2 (3)
IMDC risk, n (%)
Favorable 14 (24) 12 (20)
Intermediate 32 (54) 36 (61)
Poor 13 (22) 11 (19)
MSKCC risk, n (%)
Favorable 30 (51) 31 (52)
Intermediate 29 (49) 28 (48)
Metastasis-free interval, n (%)
<1 year 43 (73) 45 (76)
Nephrectomy, n (%)
Yes 50 (85) 51 (86)
Sites of disease, n (%)
Primary in situ 10 (17) 8 (14)
Local recurrence 3 (5) 6 (10)
Lung metastases 47 (80) 49 (83)
Lung mets only 8 (14) 8 (14)
Lymph node mets 37 (63) 37 (63)
Bone metastases 16 (27) 9 (15)
Liver metastases 8 (14) 9 (15)
No. disease sites, n (%)
1 14 (24) 13 (22)
2 21 (36) 20 (34)
3 16 (27) 17 (29)
4 8 (13) 9 (15)
Subsequent treatment, n (%)
Nivolumab 4 (7) 5 (9)
Surgery 12 (20) 15 (25)
TKI/Mtor 50 (85) 46 (78)
Pazopanib 30 (51) 31 (53)
Sorafenib 5 (9) 5 (9)
Sunitinib 17 (29) 12 (20)
Everolimus 17 (29) 22 (37)
Axitinib 13 (22) 20 (34)
Cabozantinib 0 4 (7)
PS: Performance Score; IMDC: International Metastatic Renal
Cell Carcinoma Database Consortium.
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Toxicity
No new or unexpected toxicity was observed (Table 3). Most
common Grade 3/4 adverse events for IL2/IFN/BEV and IL2/
IFN were fatigue (64 versus 61%); flu-like symptoms (37 ver-
sus 41%); dehydration (25 versus 25%); hypertension (25 ver-
sus 3%, p¼ .08) and thrombosis (7 versus 19%, p¼ .01),
respectively.
Discussion
This is the first report of combined VEGF blockade with BEV
and IL2 plus IFN immunotherapy in patients with mRCC. The
DaRenCa-1 study did not meet the primary endpoint of PFS.
The randomised phase II study demonstrated the addition of
BEV to IL2/IFN did not add efficacy. The safety profile of BEV
was consistent with prior experience. Disparate outcomes
were observed in the MSKCC favourable and intermediate-
risk groups; the differences were not likely due to a differ-
ence in subsequent therapies that were evenly distributed,
but may be due to small study number, chance, or unknown
biologic differences between MSKCC favourable and inter-
mediate-risk groups.
Previous investigations in mRCC patients of combination
therapy with BEV and IFN versus IFN monotherapy resulted in
a significantly longer PFS (8.5 versus 5.2 months) and RR (25.5
versus 13.1%) in the CALGB 90206 trial [15]. The AVOREN
Figure 2. Response characteristics. A swimmer plot depicting for each individual patient the time of response, duration of response, as well as surgery of residual
disease.
Table 2. Best overall objective response per RECIST 1.1.
IL-2/IFN/BEV IL-2/IFN
pN (%) N (%)
CR 3 (5) 2 (3) .15
PR 23 (39) 16 (27)
SD 24 (41) 23 (39)
PD 8 (14) 18 (31)
NE 1 (2) 0 (0)
CR: complete response; PR: partial response; SD: stable
disease; PD: progressive disease; NE: non-evaluable; N:
number.
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phase III trial, demonstrated similar improvements in PFS (10.2
versus 5.4 months) and RR (31 versus 13%) [14]. In both trials,
however, BEV/IFN therapy did not improve OS statistically sig-
nificant [22,23]. Our data are in line with these results, but did
not add efficacy further, despite the addition of IL2. Our data
are also in line with the non-randomized experiences with
low-dose and high-dose IL2 in combination with BEV [16,17];
BEV in combination with high-dose IL2 did not increase dur-
able responses [17], as also seen in our study. With the
extended follow-up of median 64 months, most patients
eventually progressed with this low-dose IL2 regimen. At
study closure, 7 patients (6%) had NED.
BEV has been used in combination with various agents for
first-line treatment in clear-cell mRCC, without adding effi-
cacy. The temsirolimus/BEV combination versus IFN/BEV was
not superior in the INTORACT study [24] or in the TORAVA
study, where excess toxicity of the temsirolimus/BEV combin-
ation resulted in 50% of patients had to stop treatment
[25]. The efficacy of everolimus/BEV and IFN/BEV was similar
in the RECORD 2 study [26]. PFS was similar between BEV
monotherapy (7.5 months) and BEV/temsirolimus, BEV/sorafe-
nib, or BEV/IFN in the four-arm BEST trial [27]. The combin-
ation of BEV and sunitinib resulted in excess toxicity and the
combination was not considered feasible for further develop-
ment [28,29]. Randomized phase III data for the combination
of BEV and check-point inhibitors are pending.
IL2 has consistently resulted in durable complete
responses and cure in a small subset of 5% of patients
[3,30]. However, the toxicity associated with the drug has
hindered the wide-use of IL2 and restricted its use to experi-
enced centres. IL2 has been used in combination with vari-
ous agents for first-line treatment in mRCC, without adding
efficacy. IL2/histamine did not add efficacy compared with
IL2 alone [31]. IL2 alone, or combined with IFN, compared
with the hormone drug medroxyprogesterone resulted in
similar OS in intermediate-prognosis mRCC patients [32].
Combination therapy of IL2/IFN and 5-fluorouracil (5-FU)
chemotherapy did not improve efficacy compared with IFN
alone [33]. IL2/sorafenib resulted in similar survival rates as
sorafenib alone [34]. In essence, single agent BEV and single
agent IL2 have demonstrated clinical efficacy in patients with
mRCC, but attempts to improve efficacy, in terms of
improved OS, by combination therapy with other drugs, have
so far failed, including our study.
Toxicities did not exceed those expected from each agent
alone. The most common adverse events were typical of those
observed with these drugs including fatigue, flu-like symp-
toms, diarrhoea, nausea, decreased appetite, and hypertension
[6]. The lower incidence of thrombosis in the BEV arm is surpris-
ing, and was probably obtained by chance; it emphasizes, how-
ever, that the combination therapy was safe. Averse events
were managed with supportive care in both treatment groups.
Subsequent anticancer therapy was balanced between
treatment groups after study treatment discontinuation.
Therefore, these factors are deemed unlikely to have biased
the OS results towards one treatment group. In addition, treat-
ment crossover was not allowed after determination of the pri-
mary endpoint of PFS enabling robust assessment of OS. Our
data emphasizes that IL2 therapy does not compromise subse-
quent therapy, or clinical benefit, from subsequent therapy.
Eligibility criterion for the present study was treatment
naïve mRCC patients that were not candidates for surgery. The
tumour regression following systemic therapy enabling surgery
of residual disease in 17.0% of patients should be noted, result-
ing in clinical meaningful benefit in a substantial part of
patients. These benchmarks data provide perspective when
interpreting the results from the next generation of immuno-
therapies, the check-point inhibitors. Identification of patients
who will benefit from immunotherapy is crucial. This study was
accompanied by sampling of blood, tumour and imaging bio-
markers for predictive studies, which will be published separ-
ately. Functional imaging may represent a tool for selecting
patients that will benefit, or not benefit, from therapy [35].
In conclusion, the addition of BEV, an inhibitor of VEGF, to
IL2-based immunotherapy was not associated with improve-
ments in PFS, OS, TTF, ORR, surgery of residual disease, or
patients with NED. This combination cannot be recom-
mended for treatment in patients with mRCC.
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Table 3. Adverse events.
Event
IL-2/IFN/BEV (N¼ 59),
n (%)
IL-2/ IFN (N¼ 59),
n (%)
Any grade Grade 3 or 4 Any grade Grade 3 or 4
Diarrhea 38 (64) 5 (9) 43 (73) 1 (2)
Fatigue 57 (97) 38 (64) 56 (95) 36 (61)
Nausea 53 (90) 3 (5) 52 (88) 4 (7)
Flu-like symptoms 56 (95) 22 (37) 55 (93) 24 (41)
Hypertension 32 (54) 15 (25) 10 (17) 2 (3)
Hypotension 11 (19) 1 (2) 5 (9) 0
Weight decrease 35 (59) 2 (3) 39 (66) 1 (2)
Vomiting 33 (56) 2 (3) 34 (58) 1 (2)
Stomatitis 19 (32) 0 10 (17) 0
Cough 12 (20) 1 (2) 13 (22) 1 (2)
Dyspnea 27 (46) 3 (5) 21 (36) 3 (5)
Alopecia 25 (42) 0 20 (34) 0
Confusion 18 (31) 4 (7) 18 (31) 1 (2)
Depression 19 (32) 0 16 (27) 1 (2)
Dehydration 25 (42) 15 (25) 23 (39) 15 (25)
Injection site reaction 34 (58) 0 40 (68) 0
Pain in extremity 10 (17) 0 1 (2) 0
Proteinuria 7 (12) 0 0 0
Dyspepsia 7 (12) 0 21 (36) 3 (5)
Dry skin 42 (71) 0 48 (81) 0
Rash 12 (20) 1 (2) 6 (10) 0
Thrombosis 4 (7) 4 (7) 11 (19) 11 (19)
Pruritus 31 (53) 2 (3) 36 (61) 1 (2)
Adverse events that were reported in at least 10% of the patients in either
study group are shown, regardless of whether the event was considered by
the investigator to be related to the study treatment. The severity of adverse
events was graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, v.3.0.
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